pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,740 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1633Endpoints1282Fierce Biotech605BioSpace600BioPharma Dive483raps202onclive165fda recalls107fda medwatch
therapy area
allOncology11439Rare Disease2837Immunology2638Cardiology2340Pulmonology2013Hematology1934Vaccines1695Psychiatry & CNS1122
  • Experts discuss next-generation pathology and precision care for non-small cell lung cancer in new CME podcast
    The CME podcast released on May 6, 2026 brings together Sanja Dacic, Isabel Preeshagul, and Soo-Ryum (Stewart) Yang to review recent advances in pathology for non-small cell lung cancer. The exper…
    onclive · 5mo agoNeutral↗ source
  • PeaceHealth abandons plan to outsource Oregon emergency doctors to ApolloMD after lawsuit and local opposition
    PeaceHealth, a nonprofit health system in Oregon, announced Wednesday that it will not move its emergency department staffing to the national physician staffing firm ApolloMD. The decision reverse…
    STAT · 5mo agoRegulatoryNeutral↗ source
← prev
page 67 of 70
next →
96
globenewswire health73
fda press55
Ophthalmology891
Endocrinology & Metabolism706
Pain685
Nephrology678
  • Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
    Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.
    onclive · 5mo agoNeutral↗ source
  • Expert outlines how to manage common skin and GI side effects of daraxonrasib in pancreatic cancer
    Dr Pant, MD, a professor at MD Anderson Cancer Center, discussed the safety profile of daraxonrasib, a RAS(ON) multi-selective inhibitor being studied in pancreatic ductal adenocarcinoma. The drug…
    onclive · 5mo agoNeutral↗ source
  • Pfizer halts final Trillium study, redirects R&D funds to cancer and obesity programs
    Pfizer announced it is ending the last clinical trial that originated from its 2021 purchase of Trillium Therapeutics. The company said the decision will free up cash that will be redirected to a…
    Endpoints · 5mo agoNeutral↗ source
  • Emerging Antibody-Drug Conjugates Target New Endometrial Cancer Antigens Beyond HER2
    Faculty members highlighted a growing interest in endometrial cancer therapies that go beyond the HER2 pathway. They noted that the field is expanding its focus to a broader set of molecular target…
    onclive · 5mo agoPositive↗ source
  • Expert discusses how clinicians choose between FOLFIRINOX and newly approved NALIRIFOX for metastatic pancreatic cancer
    Dr. Deirdre J. Cohen, director of GI Oncology at Mount Sinai, provides commentary on how doctors decide on frontline chemotherapy for metastatic pancreatic cancer. She notes that, as of 2026, ther…
    onclive · 5mo agoNeutral↗ source
  • Phase 1 trial of HS-10504 shows encouraging responses in EGFR C797S mutant lung cancer
    HS-10504, an investigational therapy, was evaluated in a Phase 1 study in patients with non-small cell lung cancer harboring the EGFR C797S mutation after progression on prior tyrosine kinase inhib…
    onclive · 5mo agoPositive readoutPositive↗ source
  • Microbiome startup Kanvas Biosciences secures $48 million to advance immunotherapy and malnutrition therapies
    Kanvas Biosciences announced it has closed a $48 million financing round to fund development of microbiome-based treatments targeting cancer immunotherapy response and severe malnutrition. The cap…
    Endpoints · 5mo agoDealPositive↗ source
  • Phase 3 STRIKE trial to assess disease-free survival of adjuvant tivozanib plus pembrolizumab in high-risk RCC
    Dr. Bradley McGregor, director of clinical research at the Lank Center of Genitourinary Oncology, outlined the key objectives of the ongoing phase 3 STRIKE trial (NCT06661720). The study evaluates…
    onclive · 5mo agoNeutral↗ source
  • Cytospire secures $83 million to develop pan-gamma delta T-cell engagers
    Cytospire, a British biotechnology startup, announced it raised £61 million, about $83 million, to fund the development of a new type of T-cell engager therapy. The company is targeting a "pan-gam…
    BioPharma Dive · 5mo agoDealPositive↗ source
  • Top Breast Cancer Experts Highlight Key Abstracts Ahead of 2026 ESMO Congress in Berlin
    Leading breast oncologists are sharing the abstracts they consider most important as the European Society for Medical Oncology (ESMO) Breast Cancer Congress approaches in Berlin from May 6 to 8, 20…
    onclive · 5mo agoNeutral↗ source
  • Takeda advances gene therapy, UK cancer biotech raises $83M, and new blood test may guide Wegovy use
    A Cleveland‑based biotech announced that a previously halted gene therapy program has been revived, offering a potential new option for patients as the company pursues additional studies. Takeda r…
    Endpoints · 5mo agoNeutral↗ source
  • JAK inhibitor sequencing and transplant timing in myelofibrosis discussed at 2026 conference
    Dr. Andrew Kuykendall of Moffitt Cancer Center explained how doctors decide the order of JAK inhibitor therapies and when to consider allogeneic stem cell transplant for myelofibrosis patients. At…
    onclive · 5mo agoNeutral↗ source
  • Simlukafusp Alfa plus atezolizumab shows safety but no benefit over standard care in metastatic kidney cancer
    A clinical study evaluated the novel immunocytokine simlukafusp alfa combined with atezolizumab, with or without bevacizumab, in patients with unresectable metastatic renal cell carcinoma. The com…
    onclive · 5mo agoNegative readoutNeutral↗ source
  • Study links specific dietary fats to pancreatic cancer risk, highlighting oleic acid as promoter and omega-3s as protective
    Researchers at Yale Cancer Center examined how different types of dietary fat affect pancreatic cancer development in a mouse model. Rather than focusing on total fat intake, the study compared twe…
    onclive · 5mo agoNeutral↗ source
  • Experts stress seamless coordination for relapsed multiple myeloma patients across academic and community clinics
    In a recent opinion segment, Dr. Ajay K. Nooka convened a discussion with Dr. Noopur S. Raje and Dr. Surbhi Sidana about how to best coordinate care for patients with relapsed and refractory multip…
    onclive · 5mo agoNeutral↗ source
  • Patient with EGFR-mutated NSCLC develops brain metastases after first-line EGFR inhibitor and chemotherapy
    Dr. Sands presented a case of a patient with metastatic non-small cell lung cancer that carries an EGFR mutation. The patient was treated with a first-line regimen that combined an EGFR tyrosine k…
    onclive · 5mo agoNeutral↗ source
  • Returning doctors face unexpected hurdles and new chances to improve care in their home countries
    The opinion piece argues that the common "brain drain" story about health workers leaving low‑income nations overlooks what happens when they come back. The author cites a breast surgeon who train…
    STAT · 5mo agoNeutral↗ source
  • Celcuity reports positive Phase 3 results for gedatolisib in PIK3CA-mutant breast cancer
    On May 4, 2026 Celcuity announced that its experimental drug gedatolisib achieved success in two treatment regimens for patients whose tumors carry PIK3CA mutations, according to data from its ongo…
    Endpoints · 5mo agoPositive readoutPositive↗ source
  • UCB to buy Candid Therapeutics for up to $2.2 billion, targeting bispecific antibodies for autoimmune disease
    UCB announced a deal to acquire Candid Therapeutics, a startup focused on bispecific antibody drugs, for an upfront payment of $2 billion with up to $200 million in future milestones. The transacti…
    BioPharma Dive · 5mo agoDealPositive↗ source
  • Celcuity reports positive Phase 3 data for gedatolisib, bolstering broader approval prospects
    Celcuity announced new data from an ongoing Phase 3 trial of its experimental breast cancer drug gedatolisib. The data showed that two- and three-drug combinations that included gedatolisib delaye…
    BioPharma Dive · 5mo agoPositive readoutPositive↗ source
  • UCB to buy antibody maker targeting autoimmune diseases
    UCB announced it will acquire a company that develops antibody treatments for autoimmune disorders. The deal expands UCB’s pipeline in a therapeutic area where it seeks to strengthen its market pos…
    STAT · 5mo agoDealNeutral↗ source
  • Federal appeals court rules mifepristone can only be dispensed in person, blocking mail distribution
    A federal appeals court issued a ruling that mifepristone, the medication used for medical abortions, must be provided only in person at clinics. The decision overturns the FDA regulation that had…
    STAT · 5mo agoRegulatoryNegative↗ source
  • AI drug repurposing in oncology hampered by fragmented data, curated knowledge needed
    AI tools are being used to look for new cancer indications for existing biologics, but the article notes that fragmented and disparate data sets limit even the most advanced models. Repurposing pr…
    BioPharma Dive · 5mo agoNeutral↗ source